ACI Panelists Discuss Misaligned Incentives in the Biosimilars Market
Panelists at the American Conference Institute's 2021 meeting took on the complexities of biosimilar adoption in a wide-ranging discussion.
Amgen Executive Weighs the Challenges for Interchangeable Biosimilars
A turning point for interchangeable biosimilars has arrived, as the first may be approved this year, but many questions about these agents have yet to be answered, according to Laura Sim, senior counsel for Amgen.
Pharmaceutical Pay-for-Delay Settlements "Have a Good Side"
Pay-for-delay settlements between drug companies are better regulated than in the past and are in danger of being overregulated, one panelist said.
